Dosage forms for TYK2 inhibitors

A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl) amino)-N-(methyl-d3) pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix;

• wherein the proportion of amorphous BMS-986165 to polymer in the dispersion is 4%-50% w/w amorphous BMS-986165 to 96%-50% w/w polymer;
• and
• wherein the polymer in the polymer matrix comprises one or more polymers chosen from:
• hydroxypropyl methylcellulose (HPMC),
• hypromellose phthalate (HPMC-P), and
• hydroxypropyl methylcellulose acetate succinate (HPMCAS).

A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl) amino)-N-(methyl-d3) pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix;

• wherein the polymer matrix comprises one or more of:
• hydroxypropyl methylcellulose (HPMC),
• hypromellose phthalate (HPMC-P),
• hydroxypropyl methylcellulose acetate succinate (HPMCAS), and
• methacrylic acid-ethyl acrylate copolymer (1:1);
• and
• wherein the BMS-986165 in the dosage form exhibits less than 5% degradation following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl) amino)-N-(methyl-d3) pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix;

• wherein the polymer in the polymer matrix comprises one or more polymers chosen from:
• hydroxypropyl methylcellulose (HPMC),
• hypromellose phthalate (HPMC-P),
• hydroxypropyl methylcellulose acetate succinate (HPMCAS), and
• methacrylic acid-ethyl acrylate copolymer (1:1);
• and
• wherein the BMS-986165 in the dosage form exhibits less than 5% crystallization following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.